费用高昂，一个疗程33万且不纳入医保 临床研究表明，粒子治疗有毒副作用轻、适应症范围广、肿瘤控制率高等优势，在特定部位肿瘤及传统 放疗抵抗性肿瘤的治疗中效果更好。2018 年，美国国家综合癌症网络（NCCN）指南将质子治疗作为 头颈部肿瘤和食管癌治疗的标准治疗方法之一，此前还将其纳入肝胆肿瘤治疗指南。 2025年5月，上海质子重离子医院发布《质子重离子放射治疗十周年生存报告》，其中提到，粒子放疗 患者5年总生存率近70%，初治鼻咽癌患者5年总生存率达92.9%，早期(1期)非小细胞肺癌患者5年总生 存率为70.3%。 不过这项新兴的治疗方式给患者带来了希望的同时也遭遇了现实困境。不纳入医保且接近30万一个疗程 的治疗费用，让很多患者望而却步；目前国内质子重离子每年治疗仅数千人，与我国癌症每年新发约 400多万的病例相比，仍然杯水车薪。 定向打击，国际最尖端的放射治疗技术 一道肉眼无法捕捉的重离子束，以约0.7倍光速冲出加速器。 53岁的李淑芬躺在治疗床上，这些高能带电粒子正在她体内完成一场针对癌细胞的"定向爆破"。粒子进 入人体后，会像"导弹"一样，沿着特定路径飞行，直到到达肿瘤的位置，瞬间释放大量能量。 2 ...

Core Insights - The announcement of former President Biden's prostate cancer diagnosis has heightened public awareness of prostate cancer and its implications for health management [1][2] - Prostate cancer incidence is rapidly increasing in China, particularly among older populations, with significant implications for healthcare strategies and treatment options [2][3] Group 1: Prostate Cancer Trends - Prostate cancer has become the most common malignant tumor among men in Europe and the U.S., with a notable increase in cases in China [2] - In Zhejiang Province, the ranking of prostate cancer among male cancers has risen from fourth to third place in 2023 [2] - The incidence of prostate cancer is highly correlated with age, particularly in men over 70, and is influenced by genetic factors and lifestyle choices [2] Group 2: Early Detection and Diagnosis - Early-stage prostate cancer often presents no obvious symptoms, making PSA screening crucial for early detection [2] - The early diagnosis rate for prostate cancer in China was previously below 30%, but has improved significantly with increased PSA screening, reducing late-stage diagnosis rates from over 50% to around 30% [2] Group 3: Treatment Innovations - Heavy ion therapy offers a new treatment option for localized prostate cancer, providing precise targeting of tumors with minimal damage to surrounding tissues [3] - The five-year survival rate for low-risk patients treated with heavy ion therapy exceeds 90%, and for high-risk patients, tumor control rates improve by 15%-20% compared to photon therapy [3] - Nuclear medicine treatments are being researched to target bone metastases effectively, utilizing radioactive isotopes to minimize damage to normal tissues [4] Group 4: Future Directions - The integration of advanced technologies such as gene testing and AI imaging is expected to enhance screening and treatment efficacy for prostate cancer [4] - The establishment of comprehensive treatment centers for heavy ion therapy and accelerated nuclear drug development in Zhejiang Province is anticipated to significantly improve the five-year survival rates for prostate cancer patients [4] - A shift from passive treatment to proactive health management for men is essential for effective prostate cancer control and treatment [4]